文献速递特殊人群用药

欧盟上市后妊娠与哺乳研究特征及标签影响分析

A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project.
PubMed 文献 · Drug Saf · 2022-03-31

本研究从EU PAS登记库和ClinicalTrials.gov筛选出141项关于妊娠和哺乳期用药安全的观察性研究,分析其设计特征及对药品标签的影响。结果显示仅8%的研究关注哺乳期安全,原始数据收集研究耗时约7.5年且样本量较小,仅2个产品标签因研究结果更新,现有证据生成流程效率低且影响力有限。

要点

  • 仅8%的上市后研究关注哺乳期用药安全,存在明显证据缺口。
  • 原始数据收集研究耗时约7.5年,显著长于二次数据利用研究的约2.9年。
  • 141项研究中仅2个药品标签基于研究结果更新,标签影响极低。

核心结论

  • 基于原始数据收集的研究持续时间显著更长且样本量更小(把握度更低),而关注结局相似。
  • 对于已完成的研究,对药品标签的影响非常低。
  • 当前妊娠和哺乳期证据生成过程似乎既无效率也无影响力,可能需要重新设计。

研究设计与样本

  • 从欧盟上市后研究登记库(EU PAS register)和ClinicalTrials.gov筛选关注妊娠和哺乳期用药安全评估的观察性研究。
  • 共纳入141项符合条件的观察性研究,提取相关变量信息并对相应药品标签进行影响评估。

主要发现

  • 141项研究中,63项(45%)基于原始数据收集,55项(39%)基于健康数据二次利用。
  • 仅8%的研究旨在评估哺乳期用药安全。
  • 使用二次数据收集的研究持续时间约2.9年,而原始数据收集研究约7.5年。
  • 仅2个产品标签基于研究结果更新。

临床怎么用

  • 临床药师应认识到妊娠和哺乳期用药标签信息常不充分,现有上市后研究证据对标签更新影响有限。
  • 在哺乳期用药决策时,需注意仅有少数上市后研究专门评估哺乳期安全,证据缺口明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A large proportion of medicine product labels lack information on safety in pregnancy and breastfeeding. To address this gap, pharmaceutical companies are requested to develop post-approval studies regarding the use of drugs by pregnant and breastfeeding women. OBJECTIVE: Our study aims to review key features of observational studies in pregnancy and breastfeeding and their impact on the respective medicine product labels. METHODS: Observational studies focusing on the safety evaluation of medicines used during pregnancy and breastfeeding were selected from the European Union Register of Post-Authorization Studies (EU PAS register) and ClinicalTrials.gov. We extracted information on the variables of interest and performed an impact assessment on the respective label. RESULTS: A total of 141 observational studies were eligible. Of these, 63 studies (45%) were based on primary data collection and 55 studies (39%) on secondary use of health data. A small number of studies (8%) aimed to evaluate drug safety during breastfeeding. Studies using secondary data collection lasted around 2.9 years as opposed to 7.5 years' duration for studies using primary data collection. Only two product labels were updated based on the study results. CONCLUSION: The duration is significantly longer for studies based on primary data collection, and these are also smaller in size (less power), whereas outcomes of interest are similar. For completed studies, the impact on the label was very low. Given the gap in adequate pregnancy information on product labels, the current process of generating evidence in pregnancy and breastfeeding seems neither efficient nor impactful. To support evidence-based decision making by prescribers, this current process might be redesigned.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Roque Pereira L, Durán CE, Layton D, et al. A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project. Drug Saf. 2022. PMID: 35357659. doi:10.1007/s40264-022-01154-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。